Patents Represented by Attorney Duke M. Fitch
-
Patent number: 8048907Abstract: The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.Type: GrantFiled: February 18, 2010Date of Patent: November 1, 2011Assignee: Glaxo Group LimitedInventors: Laura J Chambers, Robert Gleave, Stefan Senger, Daryl Simon Walter
-
Patent number: 7935832Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R2 represents hydrogen, halogen, C1-6 alkyl, C6-10 arylmethyl-, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkylmethyl-; and any of said C1-6 alkyl, C6-10 arylmethyl-, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkylmethyl- is optionally substituted with 1, 2 or 3 halogen atoms; and R3 represents hydrogen, fluorine or methyl; or R2 and R3 together with the carbon atoms to which they are attached form a benzene ring optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from the group consisting of C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl. The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor.Type: GrantFiled: March 20, 2008Date of Patent: May 3, 2011Assignee: Glaxo Group LimitedInventors: Robert James Gleave, David George Hubert Livermore, Daryl Simon Walter
-
Patent number: 7932282Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.Type: GrantFiled: April 2, 2008Date of Patent: April 26, 2011Assignee: Glaxo Group LimitedInventors: Paul John Beswick, David Kenneth Dean, Robert James Gleave, Andrew Peter Moses, Daryl Simon Walter
-
Patent number: 7928108Abstract: The invention provides 3-(methyloxy)-1-{4-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]butyl}-2(1H)-pyridinone of formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 3, 2008Date of Patent: April 19, 2011Assignee: Glaxo Group LimitedInventors: Gabriella Gentile, Valeria Zucchelli
-
Patent number: 7902394Abstract: Novel calcilytic compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods of using them are provided.Type: GrantFiled: December 18, 2007Date of Patent: March 8, 2011Assignee: GlaxoSmithKline LLCInventors: Robert W. Marquis, Jr., Joshi M. Ramanjulu, Robert Trout
-
Patent number: 7888347Abstract: The present invention relates to novel pyrazole derivatives of formula I having pharmacological activity as H3 antagonists processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.Type: GrantFiled: July 4, 2006Date of Patent: February 15, 2011Assignee: Glaxo Group LimitedInventors: Mark James Bamford, David Matthew Wilson
-
Patent number: 7799773Abstract: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.Type: GrantFiled: December 19, 2008Date of Patent: September 21, 2010Assignee: Glaxo Group LimitedInventors: Mark James Bamford, David Kenneth Dean, Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
-
Patent number: 7732600Abstract: Disclosed are methods for the preparation of compounds of formula (I): wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description.Type: GrantFiled: August 13, 2009Date of Patent: June 8, 2010Assignee: Glaxo Group LimitedInventors: Markus Bergauer, Barbara Bertani, Matteo Biagetti, Steven Mark Bromidge, Alessandro Falchi, Colin Philip Leslie, Giancarlo Merlo, Domenica Antonia Pizzi, Marilisa Rinaldi, Luigi Piero Stasi, Jessica Tibasco, Antonio Kuok Keong Vong, Simon Edward Ward
-
Patent number: 7718693Abstract: The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.Type: GrantFiled: July 3, 2007Date of Patent: May 18, 2010Assignee: Glaxo Group LimitedInventor: Daryl Simon Walter
-
Patent number: 7704994Abstract: The present invention relates to benzazepine derivatives of formula (I) wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.Type: GrantFiled: July 31, 2007Date of Patent: April 27, 2010Assignee: Glaxo Group LimitedInventors: Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
-
Patent number: 7696193Abstract: The present invention relates to benzazepine derivatives of formula (I) wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.Type: GrantFiled: December 18, 2003Date of Patent: April 13, 2010Assignee: Glaxo Group LimitedInventors: Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
-
Patent number: 7592346Abstract: Disclosed are methods for use of compounds of formula (I) in combination with other active substances in the treatment of CNS disorders such as depression or anxiety. wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description.Type: GrantFiled: July 2, 2008Date of Patent: September 22, 2009Assignee: Glaxo Group LimitedInventors: Markus Bergauer, Barbara Bertani, Matteo Biagetti, Steven Mark Bromidge, Alessandro Falchi, Colin Philip Leslie, Giancarlo Merlo, Domenica Antonia Pizzi, Marilisa Rinaldi, Luigi Piero Stasi, Jessica Tibasco, Antonio Kuok Keong Vong, Simon Edward Ward
-
Patent number: 7459456Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.Type: GrantFiled: March 16, 2007Date of Patent: December 2, 2008Assignee: Glaxo Group LimitedInventors: Matteo Biagetti, Alessandro Falchi, Colin Philip Leslie, Giancarlo Merlo, Domenica Antonia Pizzi, Marilisa Rinaldi, Luigi Piero Stasi, Jessica Tibasco
-
Patent number: 7439245Abstract: Disclosed is a method for use of phenyl sulfone compounds of formula (I) in the treatment of anxiety.Type: GrantFiled: May 13, 2008Date of Patent: October 21, 2008Assignee: Glaxo Group LimitedInventors: Gregor James MacDonald, Mervyn Thompson